Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells

Tumor Biology

Volumn 31, Issue 4, 2010, Pages 233-242

  Kovar, Lubomir ^a   Etrych, Tomas ^b   Kabesova, Martina ^a   Subr, Vladimir ^b   Vetvicka, David ^a   Hovorka, Ondrej ^a   Strohalm, Jiri ^b   Sklenar, Jan ^a   Chytil, Petr ^b   Ulbrich, Karel ^b   Rihova, Blanka ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

CD43; Doxorubicin; Galectin 1; Glycoproteins; HPMA

Indexed keywords

AMIDE; CARBOHYDRATE; CD45 ANTIGEN; CD7 ANTIGEN; DOXORUBICIN; FUCOSE; GALACTOSE; GALECTIN 1; GLUCOSE; GLYCOLIPID; HERMES ANTIGEN; HYDRAZONE DERIVATIVE; LECTIN; LEUKOSIALIN; MANNOSE; MEMBRANE PROTEIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; N ACETYLGALACTOSAMINE; N ACETYLGLUCOSAMINE; PEANUT AGGLUTININ; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER CONJUGATE; DOXORUBICIN-N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER CONJUGATE; DRUG CARRIER; DRUG DERIVATIVE; POLYMETHACRYLIC ACID DERIVATIVE;

AMPEROMETRY; ANIMAL CELL; ANION EXCHANGE CHROMATOGRAPHY; APOPTOSIS; ARTICLE; CELL DEATH; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHEMICAL BOND; CONJUGATION; CONTROLLED STUDY; EL4 CELL; ENDOPLASMIC RETICULUM; ERYTHRINA; ERYTHRINA CRISTAGALLI; FLOW CYTOMETRY; GLYCOSYLATION; GOLGI COMPLEX; HIGH PERFORMANCE ANION EXCHANGE CHROMATOGRAPHY; IC 50; INTRACELLULAR MEMBRANE; LECTIN BINDING; LECTIN BINDING SITE; MEMBRANE COMPONENT; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; WESTERN BLOTTING; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; METABOLISM; PATHOLOGY; T CELL LYMPHOMA;

AMIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD43; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG CARRIERS; ENDOPLASMIC RETICULUM; FLOW CYTOMETRY; GALECTIN 1; GLYCOSYLATION; GOLGI APPARATUS; LYMPHOMA, T-CELL; MICE; POLYMETHACRYLIC ACIDS;

EID: 77954633237     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0019-7     Document Type: Article

References (41)

1. Rossmann P, Rihova B, Strohalm J, Ulbrich K. Morphology of rat kidney and thymus after native and antibody-coupled cyclosporin A application (reduced toxicity of targeted drug). Folia Microbiol (Praha). 1997;42:277-87.
2. Rihova B, Strohalm J, Kovar M, et al. Induction of systemic antitumour resistance with targeted polymers. Scand J Immunol. 2005;62 Suppl 1:100-5.
3. Hopewell JW, Duncan R, Wilding D, Chakrabarti K. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer- doxorubicin-galactosamine conjugate antitumour agent. Human Exp Toxicol. 2001;20:461-70.
4. Kopecek J, Rejmanova P, Strohalm J, et al. Synthetic polymeric drugs. US Patent 5,037,883;1991.
5. Etrych T, Jelinkova M, Rihova B, Ulbrich K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J Control Release. 2001;73:89-102.
6. Minko T, Kopeckova P, Kopecek J. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm Res. 1999;16:986-96.
7. Kopecek J, Kopeckova P, Minko T, Lu Z. HPMA copolymer- anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm. 2000;50:61-81.
8. Kovar M, Kovar L, Subr V, et al. HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro. J Control Release. 2004;99:301-14.
9. Mrkvan T, Sirova M, Etrych T, et al. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor imunity. J Control Release. 2005;110:119-29.
10. Sirova M, Strohalm J, Subr V, et al. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. Cancer Immunol Immunother. 2007;56:35-47.
11. Ríhová B, Strohalm J, Hovorka O, et al. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences. J Control Release. 2008;127:110-20.
12. Kovar L, Strohalm J, Chytil P, et al. The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-Hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line. BioconjugChem. 2007;18:894-902.
13. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res. 1999;5:83-94.
14. Rihova B, Kovar L, Kovar M, Hovorka O. Cytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics. Trends Biotech. 2009;27:11-7.
15. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189-207.
16. Rihova B, Jelinkova M, Strohalm J, et al. Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymerbound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene. Bioconjug Chem. 2000;11:664-73.
17. Ríhová B, Strohalm J, Prausová J, et al. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J Control Release. 2003;91:1-16.
18. Ríhová B. Immunomodulating activities of soluble synthetic polymer-bound drugs. Adv Drug Deliv Rev. 2002;54:653-74.
19. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229.
20. Rabbani A, Finn RM, Ausio J. The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioessays. 2005;27:50-6.
21. Hovorka O, Etrych T, Subr V, Strohalm J, Ulbrich K, Rihhova B. HPMA based macromolecular therapeutics: internalization, intracellular pathway and cell death depend on the character of covalent bond between the drug and the peptidic spacer and also on spacer composition. J Drug Target. 2006;14:391-403.
22. Hovorka O, St'astny M, Etrych T, et al. Differences in the intracellular fate of free and polymer-bound doxorubicin. J Control Release. 2002;80:101-17.
23. Ulbrich K, Subr V, Strohalm J, Plocova D, Jelinkova M, Rihova B. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation. J Control Release. 2000;64:63-79.
24. Etrych T, Mrkvan T, Chytil P, Konak C, Rihova B, Ulbrich K. Polymer prodrugs based on HPMA conjugates with pH-controlled activation of doxorubicin: I. Synthesis, physicochemical characterisation and preliminary biological evaluation. J Appl Polym Sci Appl Polym Symp. 2008;109:3050-61.
25. Rejmanova P, Labsky J, Kopecek J. Aminolyses of monomeric and polymeric 4-nitrophenyl esters of N-methacryloylated amino acids. Makromol Chem. 1977;178:2159-68.
26. Rihova B, Bilej M, Vetvicka V, et al. Biocompatibility of N-(2- hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials. 1989;10:335-42.
27. Hardy MR, Townsend RR, Lee YC. Monosaccharide analysis of glycoconjugates by anion exchange chromatography with pulsed amperometric detection. Anal Biochem. 1988;170:54-62.
28. Fan JQ, Namiki Y, Matsuoka K, Lee YC. Comparison of acid hydrolytic conditions for Asn-linked oligosaccharides. Anal Biochem. 1994;219:375-8.
29. Packer NH, Lawson MA, Jardine DR, Redmond JW. A general approach to desalting oligosaccharides released from glycoproteins. Glycoconj J. 1998;15:737-47.
30. Hakomori SI. Structure and function of glycosphingolipids and sphingolipids: recollections and future trends. Biochim Biophys Acta G. 2008;1780:325-46.
31. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature. 1995;378:736-9.
32. Hernandez JD, Nguyen JT, He J, et al. Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate t cell death. J Immunol. 2006;177:5328-36.
33. Wu W, Harley PH, Punt JA, Sharrow SO, Kearse KP. Identification of CD8 as a peanut agglutinin (PNA) receptor molecule on immature thymocytes. J Exp Med. 1996;184:759-64.
34. Leffler H, Barondes SH. Specificity of binding of three soluble rat lung lectins to substituted and unsubstituted mammalian betagalactosides. J Biol Chem. 1986;261:10119-26.
35. Leppanen A, Stowell S, Blixt O, Cummings RD. Dimeric galectin-1 binds with high affinity to {alpha}2,3-sialylated and non-sialylated terminal N-acetyllactosamine units on surfacebound extended glycans. J Biol Chem. 2005;280:5549-62.
36. Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG. Cutting edge: CD7 delivers a pro-apoptotic signal during galectin-1-induced t cell death. J Immunol. 2000;165:2331-4.
37. Koh HS, Lee C, Lee KS, et al. CD7 expression and galectin-1- induced apoptosis of immature thymocytes are directly regulated by NF-[kappa]B upon T-cell activation. Biochem Biophys Res Commun. 2008;370:149-53.
38. Pace KE, Lee C, Stewart PL, Baum LG. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol. 1999;163:3801-11.
39. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumorimmune privilege. Cancer Cell. 2004;5:241-51.
40. Le QT, Shi G, Cao H, et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol. 2005;23:8932-41.
41. Salatino M, Croci DO, Bianco GNA, Ilarregui JM, Toscano MA, Rabinovich GA. Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer. Expert Opinion on Biological Therapy. 2008;8:45-57.